Adaptive hypersensitivity following long-term estrogen deprivation: Involvement of multiple signal pathways

Journal of Steroid Biochemistry and Molecular Biology

Volumn 86, Issue 3-5, 2003, Pages 265-274

  Yue, Wei ^a   Wang, Ji Ping ^a   Conaway, Mark R ^a   Li, Yuebai ^a   Santen, Richard J ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Aromatase; Long term estrogen deprivation; MAP kinase; MCF 7 cells; PI3 kinase

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 MORPHOLINO 8 PHENYLCHROMONE; AROMATASE; BINDING PROTEIN; ESTRADIOL; INITIATION FACTOR 4E BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN KINASE B; S6 KINASE; UNCLASSIFIED DRUG;

CONFERENCE PAPER; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; ESTROGEN ACTIVITY; HORMONAL REGULATION; HORMONE SENSITIVITY; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

EUKARYOTA; MINK CELL FOCUS-FORMING VIRUS;

EID: 0242710208     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-0760(03)00366-2     Document Type: Conference Paper

References (41)

1. Masamura S., Santner S.J., Heitjan D.F., Santen R.J. Estrogen deprivation causes estradiol hypersensitivity in human breast cancer cells. J. Clin. Endocrinol. Metab. 80:1995;2918-2925.
2. Herman M.E., Katzenellenbogen B.S. Alterations in transforming growth factor-α and -β production and cell responsiveness during the progression of MCF-7 human breast cancer cells to estrogen-autonomous growth. Cancer Res. 54:1994;5867-5874.
3. Shim W.-S., Conaway M., Shigeru M., Yue W., Wang J.-P., Kumar R., Santen R.J. Estradiol hypersensitivity and mitogen-activated protein kinase expression in long-term estrogen deprived human breast cancer cells in vivo. Endocrinol. 141:2000;396-405.
4. Dickson R.B., Huff K.K., Spencer E.M., Lippman M.E. Induction of epidermal growth factor-related polypeptides by 17-β estradiol in MCF-7 human breast cancer cells. Endocrinol. 118:1986;138-142.
5. Bates S.E., Davidson N.E., Valverius E.M., Freter C.E., Dickson R.B., Tam J.P., Kudlow J.E., Lippman M.E., Salomon D.S. Expression of transforming growth factor α and its messenger ribonucleic acid in human breast cancer: its regulation by estrogen and its possible functional significance. Mol. Endocrinol. 2:1988;543-555.
6. Osborne C.K., Coronado E.B., Kitten L.J., Arteaga C.I., Fuqua S.A., Ramasharma K., Marshall M., Li C.H. Insulin-like growth factor-II (IGF-II): a potential autocrine/paracrine growth factor for human breast cancer acting via the IGF-I receptor. Mol. Endocrinol. 3:1989;1701-1709.
7. Stewart A.J., Johnson M.D., May F.E., Westley B.R. Role of insulin-like growth factors and the type I insulin-like growth factor receptor in the estrogen-stimulated proliferation of human breast cancer cells. J. Biol. Chem. 265:1990;21172-21178.
8. Song R.X.-D., McPherson R.A., Adam L., Bao Y., Shupnik M., Kumar R., Santen R.J. Linkage of rapid estrogen action to MAPK activation by ERα-Shc association and Shc pathway activation. Mol. Endocrinol. 16:2002;116-127.
9. ras/MAP-kinase pathway activation by estradiol-receptor complex in MCF-7 cells. EMBO J. 15:1996;1292-1300.
10. Kato S., Endoh H., Masuhiro Y., Kitamoto T., Uchyama S., Sasaki H., Masushige S., Gotoh Y., Hishida E., Kawashima H., Metzger D., Chambon P. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science. 270:1995;1491-1494.
11. Bunone G., Briand P.A., Miksicek R.J., Picard D. Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation. EMBO J. 15:1996;2174-2183.
12. Picard D., Bunone G., Liu J.W., Donze O. Steroid-independent activation of steroid receptors in mammalian and yeast cells and in breast cancer. Biochem. Soc. Trans. 25:1997;597-602.
13. Joel P., Smith J., Sturgill T., Blenis J., Lannigan D. pp90rsk1 regulates estrogen receptor-mediated transcription through phosphorylation of Ser-167. Mol. Cell. Biol. 18:1998;1978-1984.
14. Campbell R.A., Bhat-Nakshatri P., Patel N.M., Constantinidou D., Ali S., Nakshatri H. Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance. J. Biol. Chem. 276:2001;9817-9824.
15. Musgrove E.A., Hamilton J.A., Lee C.S.L., Sweeney K.J.E., Watts C.K.W., Sutherland R.L. Growth factor, steroid, and steroid antagonist regulation of cyclin gene expression associated with changes in T-47D human breast cancer cell cycle progression. Mol. Cell. Biol. 13:1993;3577-3587.
16. Prall O.W.J., Sarcevic B., Musgrove E.A., Watts C.K.W., Sutherland R.L. Estrogen-induced activation of cdk4 and cdk2 during G1-S phase progression is accompanied by increased cyclin D1 expression and decreased cyclin-dependent kinase inhibitor association with cyclin E-cdk2. J. Biol. Chem. 272:1997;10882-10894.
17. Prall O.W.J., Rogan E.M., Musgrove E.A., Watts C.K.W., Sutherland R.L. c-Myc or cyclin D1 mimics estrogen effects on cyclin E-Cdk2 activation and cell cycle reentry. Mol. Cell. Biol. 18:1998;4499-4508.
18. Kip1 abrogates antiestrogen-mediated cell cycle arrest in human breast cancer cells. Proc. Natl. Acad. Sci. U.S.A. 97:2000;9042-9046.
19. Cicatiello L., Addeo R., Altucci L., Petrizzi V.B., Boccia V., Cancemi M., Germano D., Pacilio C., Salzano S., Bresciani F., Weisz A. The antiestrogen ICI 182,780 inhibits proliferation of human breast cancer cells by interfering with multiple, sequential estrogen-regulated processes required for cell cycle completion. Mol. Cell. Endocrinol. 165:2000;199-209.
20. Foster J.S., Henley D.C., Bukovsky A., Seth P., Wimalasena J. Multifaceted regulation of cell cycle progression by estrogen: regulation of cdk inhibitors and cdc25A independent of cyclin D1-cdk4 function. Mol. Cell. Biol. 21:2001;794-810.
21. Jeng M.-H., Yue W., Eischeid A., Wang J.-P., Santen R.J. Role of MAP kinase in the enhanced cell proliferation of long-term estrogen deprived human breast cancer cells. Breast Cancer Res. Treat. 62:2000;167-175.
22. Coutts A.S., Murphy L.C. Elevated mitogen-activated protein kinase activity in estrogen-nonresponsive human breast cancer cells. Cancer Res. 58:1998;4071-4074.
23. Yue W., Wang J.-P., Conaway M., Masamura S., Li Y., Santen R.J. Activation of the MAPK pathway enhances sensitivity of MCF-7 breast cancer cells to the mitogenic effect of estradiol. Endocrinology. 143:2002;3221-3229.
24. Huang W., Erikson R.L. Constitutive activation of MEK1 by mutation of serine phosphorylation sites. Proc. Natl. Acad. Sci. U.S.A. 91:1994;8960-8963.
25. McCormick F. Activators and effectors of ras p21 proteins. Curr. Opin. Genet. Dev. 4:1994;71-76.
26. Kodaki T., Woscholski R., Hallberg B., Rodriguez-Viciana P., Downward J., Parker P.J. The activation of phosphatidylinositol 3-kinase by Ras. Curr. Biol. 4:1994;798-806.
27. s6k. EMBO J. 16:1997;3693-3704.
28. Yue W., Santen R.J., Wang J.-P., Hamilton C.J., Demers L.M. Aromatase within the breast. Endocr. Relat. Cancer. 6:1999;157-164.
29. Mueller H., Flury N., Eppenberger-Castori S., Kueng W., David F., Eppenberger U. Potential prognostic value of mitogen-activated protein kinase activity for disease-free survival of primary breast cancer patients. Int. J. Cancer (Pred. Oncol.). 89:2000;384-388.
30. Jones S.M., Kazlauskas A. Growth-factor-dependent mitogenesis requires two distinct phases of signaling. Nat. Cell Biol. 3:2001;165-172.
31. Gille H., Downward J. Multiple Ras effector pathways contribute to G1 cell cycle progression. J. Biol. Chem. 274:1999;22033-22040.
32. Toker A. Protein kinases as mediators of phosphoinositide 3-kinase signaling. Mol. Pharmacol. 57:2000;652-658.
33. Klijn J.G., Berns P.M., Schmitz P.I., Foekens J.A. The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review on 5232 patients. Endocrine Rev. 13:1992;3-17.
34. Nicholson R.I., McClelland R.A., Gee J.M., Manning D.L., Cannon P., Robertson J.F., Ellis I.O., Blamey R.W. Epidermal growth factor receptor expression in breast cancer: association with response to endocrine therapy. Breast Cancer Res. Treat. 29:1994;117-125.
35. Benz C.C., Scott G.K., Sarup J.C., Johnson R.M., Tripathy D., Coronado E., Shepard H.M., Osborne C.K. Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res. Treat. 24:1993;85-95.
36. Leitzel K., Teramoto Y., Konrad K., Chinchilli V.M., Volas G., Grossberg H., Harvey H., Demers L., Lipton A. Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer. J. Clin. Oncol. 13:1995;1129-1135.
37. Witters L.M., Kumar R., Chinchilli V.M., Lipton A. Enhanced anti-proliferative activity of the combination of tamoxifen plus HER-2-neu antibody. Breast Cancer Res. Treat. 42:1997;1-5.
38. Kunisue H., Kurebayashi J., Otsuki T., Tang C.K., Kurosumi M., Yamamoto S., Tanaka K., Doihara H., Shimizu N., Sonoo H. Anti-HER2 antibody enhances the growth inhibitory effect of anti-oestrogen on breast cancer cells expressing both oestrogen receptors and HER2. Br. J. Cancer. 82:2000;46-51.
39. Massarweh S., Shou J., DiPietro M., Mohsin S.K., Hilsenbeck S.G., Wakeling A.E., Brown P.H., Osborne C.K., Schiff R. Targeting the epidermal growth factor receptor pathway improves the anti-tumor effect of tamoxifen and delays acquired resistance in a xenograft model of breast cancer (abstract 18). Breast Cancer Res. Treat. 76:2002;S33.
40. Balthazart J., Baillien M., Ball G.F. Phosphorylation processes mediate rapid changes of brain aromatase activity. J. Steroid Biochem. Mol. Biol. 79:2001;261-277.
41. Shouzu M., Sumitani H., Murakami K., Segawa T., Yang H.-J., Inoue M. Regulation of aromatase activity in bone-derived cells: possible role of mitogen-activated protein kinase. J. Steroid Biochem. Mol. Biol. 79:2001;61-65.